• AAPL 194.27
  • TSLA 242.6036
  • AMZN 146.88
  • BTC-USD 43272.5703
  • ETH-USD 2355.7637
  • EURUSD 1.0782
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. US /
  3. IPSEF.US

Ipsen S.A (IPSEF PINK) stock market data APIs

$108.75 0(0%) as of December 7, 2023

Ipsen S.A Financial Data Overview

108.75
108.75
-
108.75
108.75
108.75-123.75
9 244 M
20.6357
82 690 K
3 282 M
2.1499
0.0118
0.587
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'IPSEF',
Type: 'Common Stock',
Name: 'Ipsen S.A',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000GNNSP7',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - Specialty & Generic',
GicSector: NULL,
GicGroup: NULL,
GicIndustry: NULL,
GicSubIndustry: NULL,
HomeCategory: NULL,
IsDelisted: false,
}

Ipsen S.A Fundamental Data is available in our Financial Data APIs

  • Net Revenue 3 282 M
  • EBITDA 1 064 M
  • Earnings Per Share 5.27
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $49.99 See full price
Get sample
of Fundamental API Data

Get Ipsen S.A Earnings via APIs

  • Latest Release 2021-06-30
  • EPS/Forecast 0

Get Ipsen S.A End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Ipsen S.A latest news via APIs

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen Pharma Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Art...

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

Ipsen Pharma New Drug Application granted priority review with PDUFA date set for June 10, 2024 European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for e...
Still have any questions?

Or need any other data for equities, funds or ETFs? Send us an email.

support@eodhistoricaldata.com